New report calls Canada’s alternative protein industry ‘hotbed of innovation and key country to do business in’
Game Changers is the first report to compile Canada’s extensive activity in alternative protein development in one place.
ImmunoFyx is a private early-stage biotechnology company focused on novel antibody fusion proteins targeting highly metastatic solid tumours. Up to 90% of cancer deaths are associated with metastases for which there are few treatment options. ImmunoFyx utilizes unique combinations of endogenous anti-cancer proteins to reduce tumour growth, angiogenesis and metastases.
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.